Japan OTC Drug Deregulation Leads To Hot Price Competition
This article was originally published in PharmAsia News
Deregulation of over-the-counter drugs in Japan appears to have had the government's desired effect as stores do battle in competition over prices. One supermarket, newly allowed to sell certain OTC drugs such as painkillers and cold remedies, became the latest to join the competition by announcing it would cut prices of such products by as much as 55 percent. Drug stores, also now allowed to sell most OTC drugs without having to have a pharmacist on the premises, also have joined the battle by offering discounts and extending store hours. (Click here for more - a subscription may be required
You may also be interested in...
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.